Benzinga · Sep 4, 2026
Why Is Belite Bio Stock Soaring Friday?
Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.
BL
NASDAQ · BLTE
Belite Bio, Inc
Healthcare · Biotechnology
$183.16
Down-$8.09 (-4.42%)
Updated Sep 11, 2026, 12:26 AM
SID Score
5.3/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 5.24B
- P/E ratio
- -99.11
- Dividend yield
- 0.00%
- 52-week range
- $130.00 – $198.58
- Volume
- 236.75K
- Avg. volume
- 136.46K
Price performance
BLTE price history
1M range · 19 trading sessions · Daily adjusted prices
BLTE closed at $183.16 after 19 trading sessions, up 10.15% for the selected period.
- Last close
- $183.16
- Period change
- +10.15%
- Period low
- $151.72
- Period high
- $193.61
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $191.09 | $191.30 | $181.80 | $183.16 | 236.75K |
| Sep 8, 2026 | $192.71 | $198.58 | $187.51 | $192.85 | 571.48K |
| Sep 4, 2026 | $172.77 | $193.88 | $172.77 | $193.61 | 738.95K |
| Sep 3, 2026 | $161.25 | $171.78 | $159.86 | $171.09 | 203.42K |
| Sep 2, 2026 | $157.99 | $163.70 | $157.3325 | $160.66 | 212.68K |
| Sep 1, 2026 | $154.49 | $157.19 | $153.85 | $156.70 | 114.14K |
| Aug 31, 2026 | $150.94 | $158.39 | $150.16 | $155.71 | 146.18K |
| Aug 28, 2026 | $156.75 | $158.235 | $151.15 | $151.72 | 171.27K |
| Aug 27, 2026 | $156.69 | $158.15 | $154.02 | $157.01 | 106.5K |
| Aug 26, 2026 | $160.32 | $162.435 | $155.3201 | $156.69 | 269.76K |
| Aug 25, 2026 | $161.09 | $163.885 | $160.22 | $161.68 | 61.86K |
| Aug 24, 2026 | $162.385 | $162.385 | $157.77 | $158.87 | 135.34K |
| Aug 21, 2026 | $163.50 | $164.81 | $160.44 | $161.06 | 111.22K |
| Aug 20, 2026 | $165.75 | $169.445 | $159.98 | $161.94 | 167.32K |
| Aug 19, 2026 | $163.91 | $170.86 | $163.44 | $168.55 | 126.09K |
| Aug 18, 2026 | $161.81 | $165.3425 | $160.15 | $162.57 | 96.28K |
| Aug 17, 2026 | $162.11 | $166.08 | $161.00 | $163.21 | 180.99K |
| Aug 14, 2026 | $166.51 | $167.00 | $159.00 | $162.80 | 228.8K |
| Aug 13, 2026 | $178.94 | $178.94 | $163.20 | $166.28 | 491.66K |
Latest BLTE news
The latest Smart Investors Daily articles mentioning BLTE.
Stock researchCompany · Overview
BLTE research
Overview
Company profile and research snapshot.
Company profile
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $191.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Mizuho | Outperform | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 14, 2026 | Morgan Stanley | Overweight | — |
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 4, 2026
This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.
Benzinga · Sep 4, 2026
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303
Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.
Yahoo · Sep 3, 2026
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date. At the company’s 2026 Commercial Day, Chairman and CEO
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
